Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 14-week, Randomized, Double-blind, Placebo-controlled, Multi-center Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily (O.D.) in Patients With Fibromyalgia

NCT00612170 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00612170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00612170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 14-week, Randomized, Double-blind, Placebo-controlled, Multi-center Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily (O.D.) in Patients With Fibromyalgia
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
May 31, 2009
Enrollment
1,129 (actual)
Sites
145

Conditions

As the registry lists them; a condition with its own page is linked.

fibromyalgia